U.S. FDA Approves DARZALEX(R) (daratumumab) Split-Dosing Regimen

Revised product label allows for new administration option HORSHAM, Pa., Feb. 12, 2019 -- (Healthcare Sales & Marketing Network) -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FD... Biopharmaceuticals, Oncology, FDA Janssen Pharmaceutical, DARZALEX, daratumumab, multiple myeloma

https://salesandmarketingnetwork.com/news_release_bs.html?ID=2044753

Source: HSMN NewsFeed - February 12, 2019 Category: Pharmaceuticals Source Type: news

More News: Cancer & Oncology | Food and Drug Administration (FDA) | Marketing | Myeloma | Pharmaceuticals